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Abstract 
The apigenin-phospholipid phytosome (APLC) was developed to improve the aqueous solubility, 
dissolution, in vivo bioavailability, and antioxidant activity of apigenin. The APLC synthesis was guided by 
a full factorial design strategy, incorporating specific formulation and process variables to deliver an 
optimized product. The design-optimized formulation was assayed for aqueous solubility, in vitro 
dissolution, pharmacokinetics, and antioxidant activity. The pharmacological evaluation was carried out 
by assessing its effects on carbon tetrachloride-induced elevation of liver function marker enzymes in a 
rat model. The antioxidant activity was assessed by studying its effects on the liver antioxidant marker 
enzymes. The developed model was validated using the design-optimized levels of formulation and 
process variables. The physical-chemical characterization confirmed the formation of phytosomes. The 
optimized formulation demonstrated over 36-fold higher aqueous solubility of apigenin, compared to that 
of pure apigenin. The formulation also exhibited a significantly higher rate and extent of apigenin release 
in dissolution studies. The pharmacokinetic analysis revealed a significant enhancement in the oral 
bioavailability of apigenin from the prepared formulation, compared to pure apigenin. The liver function 
tests indicated that the prepared phytosome showed a significantly improved restoration of all carbon 
tetrachloride-elevated rat liver function marker enzymes. The prepared formulation also exhibited 
antioxidant potential by significantly increasing the levels of glutathione, superoxide dismutase, catalase, 
and decreasing the levels of lipid peroxidase. The study shows that phospholipid-based phytosome is a 
promising and viable strategy for improving the delivery of apigenin and similar phytoconstituents with 
low aqueous solubility. 
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Abstract 
The apigenin-phospholipid phytosome (APLC) was developed to improve the aqueous solubility, 
dissolution, in vivo bioavailability, and antioxidant activity of apigenin. The APLC synthesis was 
guided by a full factorial design strategy, incorporating specific formulation and process 
variables to deliver an optimized product.  The design-optimized formulation was assayed for 
aqueous solubility, in vitro dissolution, pharmacokinetics, and antioxidant activity. The 
pharmacological evaluation was carried out by assessing its effects on carbon tetrachloride-
induced elevation of liver function marker enzymes in a rat model. The antioxidant activity was 
assessed by studying its effects on the liver antioxidant marker enzymes. The developed model 
was validated using the design-optimized levels of formulation and process variables. The 
physical-chemical characterization confirmed the formation of Phytosomes. The optimized 
formulation demonstrated over 36-fold higher aqueous solubility of apigenin, compared to that 
of pure apigenin. The formulation also exhibited a significantly higher rate and extent of 
apigenin release in dissolution studies. The pharmacokinetic analysis revealed a significant 
enhancement in the oral bioavailability of apigenin from the prepared formulation, compared to 
pure apigenin. The liver function tests indicated that the prepared phytosome showed a 
significantly improved restoration of all carbon tetrachloride-elevated rat liver function marker 
enzymes. The prepared formulation also exhibited antioxidant potential by significantly 
increasing the levels of glutathione, superoxide dismutase, catalase, and decreasing the levels of 
lipid peroxidase. The study shows that phospholipid-based phytosome is a promising and viable 
strategy for improving the delivery of apigenin and similar phytoconstituents with low aqueous 
solubility. 
*Graphical Abstract 
1. Introduction
Apigenin is a hydrophobic, polyphenolic flavonoid compound commonly found in fruits, 
vegetables, tea, chamomile, wheat sprouts etc. (Shukla and Gupta, 2010).  Apigenin-containing 
preparations are marketed as dietary and herbal supplements (Peterson and Dwyer, 1998). It has 
been demonstrated to possess anti-oxidant (Prince Vijeya Singh et al., 2004; Stanojević et al., 
2009), anti-microbial (Taleb-Contini et al., 2003), anti-inflammatory (Funakoshi-Tago et al., 
2011; Rithidech et al., 2012), anti-proliferative (Johnson and Gonzalez de Mejia, 2013), anti-
viral (Shibata et al., 2014), antidiabetic (Choi et al., 2014), and tumor inhibitory activities 
(Choudhury et al., 2013; Ruela-de-Sousa et al., 2010). 
The clinical potential of apigenin is stifled by its poor aqueous solubility, rapid metabolism, 
and low oral bioavailability. Apigenin has an aqueous solubility of less than 2.16 µg/mL, and 
rated as a Class II drug, based on the Biopharmaceutics Classification System (BCS) (Zhang et 
al., 2012). After oral administration in rats, apigenin undergoes rapid metabolism to key 
metabolites, such as p-hydroxy phenyl propionic acid, p-hydroxy cinnamic acid, and p-hydroxy 
benzoic acid (Griffiths and Smith, 1972). Furthermore, it demonstrated only 51% bioavailability 
after oral administration of Flos chrysanthemi extract (100 mg/kg) in rats (Chen et al., 2012). 
Thus, it is necessary to overcome these limitations using novel formulation strategies to improve 
apigenin delivery. 
Several formulation strategies and techniques e.g. liposomes (Arsić et al., 2011), nanocrystal 
gel formulations (Al Shaal et al., 2011), and self-micro emulsifying drug delivery systems 
(SMEDDS) (Zhao et al., 2013) have been investigated to improve the delivery of apigenin. 
Munyendo et al reported that the formulation of D-α-tocopherol acid and polyethylene glycol 
1000 succinate (TPGS) stabilized the mixed micelles of apigenin and phospholipids in their 
evaluation anticancer properties (Munyendo et al., 2013). Karthivashan et al prepared 
‘flavonosomes’ (phytosomes loaded with multiple flavonoids) using phosphatidylcholine as a 
carrier, and evaluated their in vitro pharmacokinetics and toxicity (Karthivashan et al., 2016). 
Shen et al evaluated a novel topical delivery system for apigenin by using soy lecithin-based 
ethosomes (Shen et al., 2014).  The authors demonstrated a superior skin targeting with the 
prepared ethosomes. Additionally, apigenin-loaded ethosomes also showed a significant 
reduction of cyclooxygenase-2 levels in mouse skin inflammation induced by ultraviolet B 
(UVB) light. Pawlikowska-Pawlega et al studied the interaction of apigenin within liposomes 
formed with dipalmitoylphosphatidylcholine (DPPC) using FTIR spectroscopy, 
1
H-NMR, and
EPR techniques, and also investigated its chemopreventive activity via changing the fluidity of 
tumor cell membranes (Pawlikowska-Pawlega et al., 2013). 
While these formulation methods were shown to improve the solubility, dissolution, or in 
vitro activity of apigenin , a systematic evaluation of the bioavailability and in vivo 
pharmacokinetics of apigenin is missing in literature; this is particularly true for oral 
administration of apigenin, or novel formulations of apigenin. 
Semalty et al reviewed the potential benefits of pharmacosomes, novel lipid-based drug 
delivery systems, in improving the biopharmaceutical properties of several drugs (Semalty et al., 
2009). Previous studies have demonstrated that an appropriate carrier system like phospholipids 
can improve the aqueous solubility, permeability, and overall bioavailability of such compounds. 
The studies with Centella asiatica (Saoji et al., 2016), matrine (Ruan et al., 2010), oxymatrine 
(Yue et al., 2010), curcumin (Zhang et al., 2013), catechin (Semalty et al., 2012), chrysophanol 
(Singh et al., 2012), naringenin (Semalty et al., 2014) have shown that molecular aggregation 
with phospholipids increased their oral bioavailability by improving the aqueous solubility, 
permeability, and other properties of these phytochemicals. Semalty et al discussed the 
usefulness of supramolecular phospholipids–polyphenolics adducts (PHYTOSOME®) in
improving the solubility and permeability of low water-soluble polyphenolic compounds across a 
broad pharmacological spectrum (Semalty et al., 2010).  In a recent review, Semalty A. provided 
a comprehensive analysis of cyclodextrin-, and phospholipid-based aggregates in the 
enhancement of solubility, dissolution, and overall bioavailability of Biopharmaceutical 
Classification System (BCS) Class II and Class IV drugs (Semalty, 2014). 
The present work aims to formulate, optimize, characterize an apigenin–phospholipid 
phytosome (APLC), and evaluate the optimized formulation for both enhanced aqueous 
solubility and oral bioavailability of apigenin in a rat model. Additionally, a preliminary 
pharmacological analysis was carried out to evaluate the in vivo antioxidant potential after oral 
administration of APLC in rats. 
2. Materials and Methods
2.1. Materials 
Apigenin was obtained from Shandong Northwest Manufacturing Co., China. Phospholipon
®
90H was obtained from Lipoid GmbH, Ludwigshafen, Germany. 1, 4 – dioxane, 2, 2-diphenyl-1-
picrylhydrazyl (DPPH), 5,5′-dithiobis-2-nitrobenzoic acid (DTNB, Ellman’s Reagent), and 3-(2-
Pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p′-disulfonic acid monosodium salt hydrate (FerroZine™ 
Iron Reagent) were obtained from Loba Chemie Pvt. Ltd., Mumbai, India. n-hexane, n-octanol, 
thiobarbituric acid, and trichloroacetic acid were purchased from Sigma-Aldrich Corporation, St. 
Louis, MO. All other chemicals used were of analytical grade. 
2.2. Formulation of apigenin-phospholipid phytosome 
The APLC was prepared using different molar ratios of (1:1, 1:2 and 1:3) based on earlier 
reported techniques (Bhattacharyya et al., 2014; Maiti et al., 2007). Briefly, accurately weighed 
amounts of apigenin and phospholipid were placed into a 100 mL round bottom flask, and 
dissolved in 20 mL of a mixture of 1, 4–dioxane:methanol (14:6). The reaction temperature of 
the reflux was controlled at 40 ºC, 50 ºC, or 60 ºC using a water bath for two h. The flask 
contents were then concentrated to obtain a dry residue. This dried material was dissolved in a 50 
mL mixture of chloroform: methanol (45:5). The solution was then concentrated to 2-3 mL and 
poured into 100 mL of n-hexane. The resulting APLC was precipitated and filtered. 
Subsequently, the phytosome was dried completely under vacuum at 40 ºC. The dried APLC 
(yield ~90% w/w) was transferred to a light-protected (amber) glass vial purged with nitrogen, 
and stored at room temperature. 
2.3. The extent of Apigenin incorporation in the prepared APLC (% yield) 
An accurately weighed amount of APLC (equivalent to 10 mg of apigenin) was added to 5 mL of 
chloroform. The formed phytosome and the unreacted phospholipid dissolves in chloroform, but 
the free (non-aggregated) apigenin remains practically insoluble in chloroform (Tan et al., 2012). 
The dispersion was filtered and the free or non–aggregated apigenin was separated as a 
precipitate. This non-aggregated apigenin was dissolved in methanol and assayed using a UV-
visible spectrophotometer (Model: V-630, JASCO International Co. Ltd., Tokyo, Japan) at 335 
nm for apigenin. 
2.4. Full-factorial design (32)
A full factorial design was adopted to study the overall influence of specific independent 
variables, viz., drug: phospholipids ratio (X1, w: w), and temperature (X2, ºC) on the extent of 
apigenin incorporation (% yield). The two independent variables (X1 and X2) were selected at 
three levels, coded as -1 (low), 0 (middle), and +1 (higher), resulting in a 3
2
 factorial design of
nine possible combinations. The extent of apigenin incorporation (% yield) was defined as the 
dependent variable. The experimental trials were performed using all nine possible combinations 
of the selected variables. The mathematical model containing coefficient effects, interactions, 
and polynomial terms was analyzed to assess the response using the following equation: 
                                
where   is the dependent variable,   is the coefficient of the independent variable  . The main 
effects (   and   ) represent the possible aggregate effect of both factors as they change 
independently from their low to high level. The interaction term (    ) shows how the response 
changes when two factors are simultaneously changed. The polynomial terms (    and    ) 
describes the non-linearity. The design levels and the real values of the independent variables are 
shown in Table 1. The composition of experimental trials along with obtained yield (%) values 
are shown in the Table 2. 
2.5. Physicochemical characterization 
2.5.1. Particle size analysis and zeta potential 
Photon Cross-Correlation Spectroscopy (PCCS) with dynamic light scattering was used to 
analyze the particle size distribution of the prepared APLC. Briefly, about 5 mg of APLC 
powder was dispersed in 10 mL deionized water in a sample vial. The sample vial was inserted 
manually into the sample chamber of the analyzer (Model: NANOPHOX, Sympatec GmbH, 
Clausthal-Zellerfeld, Germany) with a sensitivity range of 1 nm to10 μm. The count rate was 
optimized by selecting an appropriate position of the sample vial with the help of the associated 
software. All measurements were carried out at a fixed temperature of 25 ºC. 
 The zeta potential of the APLC powder was measured using a Dynamic Light Scattering 
(DLS) zeta potential and nano particle analyzer (Model: NanoPlus
TM
-2, Particulate Systems, 
Norcross, GA, USA) with a zeta potential range of -200 to +200 mV. 
2.5.2. Differential scanning calorimetry (DSC) 
The samples of pure apigenin, pure Phospholipon
®
 90H, the physical mixture (PM) of apigenin 
and Phospholipon
®
 90H, and the APLC were analyzed for their thermal behavior using a 
differential scanning calorimeter (Model: DSC-1 821e, Mettler-Toledo AG, Analytical, 
Schwerzenbach, Switzerland). Dried nitrogen (50 mL/min) was used as a purge gas. The 
instrument was calibrated for the heat flow and heat capacity with high-purity indium standard 
using standard procedures reported elsewhere. Each sample (2.0 ± 0.2 mg) followed a single 
heating cycle with temperature ramping from 40 °C to 400 °C at a heating rate of 10 °C min
-1
. 
The analysis of the event peaks for all the samples was carried out using the software 
accompanying the instrument. 
2.5.3. Fourier transform infrared spectroscopy (FTIR) 
The molecular interactions between the formulation components were analyzed by obtaining the 
infrared scans of pure apigenin, Phospholipon
®
 90H, PM, and APLC on a FTIR 
spectrophotometer (Model: FTIR-8300, Shimadzu Corporation, Kyoto, Japan). Briefly, 
individual samples (~2 mg) were uniformly mixed with potassium bromide (KBR, ~200mg) and 
compressed under pressure of 10 Ton/nm
2
 to prepare circular transparent discs. The samples 
were previously dried in a hot air oven at 50 °C for 2 h to theoretically remove the influence of 
residual moisture, if any. Each analysis included 45 scans, at a resolution of 4 cm
−1
 in the 
wavelength range 4000 to 400 cm
−1
. The data was analyzed using IRsolution FTIR control 
software (version: 1.10) associated with the instrument. 
2.5.4. Proton nuclear magnetic resonance (1H-NMR)
The proton nuclear magnetic resonance (
1
H-NMR) spectra of pure apigenin, pure Phospholipon
®
90H, PM, and APLC were obtained on a 400 MHz FT-NMR spectrophotometer (Bruker Avance 
II, Bruker BioSpin, Billerica, MA) with a temperature range of -90 °C to 80 °C . All samples 
were analyzed at 292 K (18.85 °C). 
2.5.5. Powder x-ray diffractometry (PXRD) 
The samples of pure apigenin, Phospholipon
®
 90H, PM, and APLC were analyzed for their
polymorphic state by obtaining their x-ray diffraction scans. This was done using a powder x-ray 
diffractometer (Model: D8 ADVANCE, Bruker AXS, Inc., Madison, WI, USA) operating with a 
Bragg-Brentano geometry (θ/2θ) optical setup. Briefly, the samples were mounted uniformly as a 
thin layer on the sample holder. A one dimensional detector (LYNXEYE
TM
) for x-ray
diffraction, based on Bruker AXS’ compound silicon strip technology was used to monitor 
diffraction. The samples were irradiated with a monochromatic CuKβ radiation (λ=1.5406Å) at 
an operating voltage and amperage of 30 mV and 10 mA, respectively. The samples were 
scanned with the diffraction angle increasing from 3° to 60°, 2θ angle, with a step-angle of 0.04° 
2θ and a count time of 5 seconds. The angular spin for the samples was Φ = 360°. 
2.5.6. Solubility analysis 
The aqueous solubilities of pure apigenin and apigenin in the prepared APLC were determined 
by a method similar to that described earlier (Saoji et al., 2016). Briefly, an excess of apigenin or 
APLC were added to 5 mL of water or n-octanol in sealed glass containers at room temperature 
(25 °C). The liquid was agitated for 24 h, followed by centrifugation for 25 min at 1500 rpm. 
The supernatant was filtered through a membrane filter (0.45 µ). 1 mL of this filtrate, after 
appropriate dilutions, was assayed using a UV-visible spectrophotometer (Model: V-630, 
JASCO International Co. Ltd., Tokyo, Japan) at 335 nm for apigenin. 
2.6 Functional characterization 
2.6.1 In vitro dissolution studies 
The in vitro dissolution behavior of pure apigenin, and apigenin in the prepared APLC was 
analyzed using a dialysis method reported earlier (Maiti et al., 2009). Briefly, a dialysis 
membrane (LA393, Dialysis Membrane-70, Average diameter 17.5 mm, Average flat width  
28.46 mm, and capacity ~ 2.41 mL/cm; HiMedia Laboratories, Mumbai, India), which retains 
molecules >12,000 kDa was used to prepare dialysis bags for the samples. The membrane was 
washed according to the manufacturer guidelines. 2 mL of apigenin suspension (2 mg/mL) or 
APLC (~4 mg apigenin) was added to dialysis bag and tied. The tied membrane bag was 
suspended into a beaker containing phosphate buffer saline (PBS, 200 mL, pH 7.4) with 
(Tween
®
 20, 1% w/v). The contents of the beakers were stirred at 50 rpm using a magnetic stirrer
at 37 ± 1°C. At predetermined intervals, 5 mL aliquots were withdrawn and assayed using a UV-
visible spectrophotometer (Model: V-630, JASCO International Co. Ltd., Tokyo, Japan) at 
335nm to estimate the release of apigenin. 
2.6.2 In vivo antioxidant activity 
The influence of pure apigenin, and the prepared APLC on the liver function test, and their in vivo 
antioxidant activity was evaluated using the method previously reported in literature (Maiti et al., 2007; 
Maiti et al., 2009). 
2.6.2.1 Animals 
Male and female albino rats (Wistar strain, bred in-house, 150-200 g) were employed for the 
evaluation of in vivo antioxidant activity of pure apigenin and APLC. All animals were housed in 
colony cages in groups of four at controlled temperature (25 ± 5 °C) and humidity (50 ± 5%RH) 
conditions, with a 12 h light/dark cycle. The food (pellet chow, Brooke Bond, Lipton, India) and 
water were provided ad libitum. The experimental protocol (UDPS/IAEC/2013–14/05, dated 
February 14, 2014) for the study was approved by the Institutional Animal Ethics Committee 
(IAEC) of the University Department of Pharmaceutical Sciences (UDPS), R. T. M. Nagpur 
University, Nagpur, India. The experimental protocols were followed according to the ethical 
guidelines provided by the Committee for the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA). 
2.6.2.2 Dosing 
The animals were divided into four groups, with six animals in each group. Group I and Group II 
animals received Tween
®
 20 (1% v/v, p.o.) diluted with distilled water for seven days. On the 
seventh day, Group II animals received a single dose of a mixture of CCl4 and olive oil (1:1, 5 
mL/kg, i.p.). Group I served as negative control and Group II served as the positive control. 
Group III animals received pure apigenin (25 mg/kg, p.o.) suspension in distilled water with 
Tween
®
 20 (1% v/v) for seven days. On the seventh day, this group also received a single dose of 
a mixture of CCl4 and olive oil (1:1, 5 mL/kg, i.p.). Group IV animals received APLC (~25 
mg/kg apigenin, p.o.) for seven days. On the seventh day, this group also received a single dose 
of a mixture of CCl4 and olive oil (1:1, 5 mL/kg, i.p.). After 24 h of CCl4 administration, all the 
animals were anaesthetized using ether. The blood samples of all animals were collected from 
the retro orbital plexus and centrifuged. The animals were subsequently euthanized by cervical 
decapitation. The supernatant plasma samples were used for the liver function test. Additionally, 
the livers of all animals were dissected immediately and washed in ice cold saline. The livers 
were homogenized in 0.1 M phosphate buffer saline (PBS, pH 7.4) and centrifuged to obtain a 
clear supernatant. This solution was used to estimate the in vivo antioxidant marker enzymes. 
2.6.2.3 Liver marker enzyme estimation (liver function test) 
The influence of pure apigenin and APLC on rat liver function was evaluated by quantitative 
determination of serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic 
transaminase (SGPT), serum alkaline phosphatase (SALP), and total bilirubin. A method 
previously described in literature was used to estimate SGOT and SGPT levels (Reitman and 
Frankel, 1957). Briefly, 0.5 mL of substrate [α-L-alanine (200 mM) for SGOT, or L-aspartate 
(200 mM) with 2 mM α-ketoglutarate for SGPT] was incubated for 5 min at 37 °C. 0.1 mL rat 
plasma was added to the substrate and the volume was adjusted to 1 mL with sodium phosphate 
buffer (pH 7.4, 0.1 M). The mixture was incubated for either 30 min (SGPT) or 60 min (SGOT). 
2, 4-dinitrophenylhydrazine (DNPH, 0.5 mL, 1 mM) was then added to this reaction mixture and 
left for additional 30 min at room temperature. Finally, 5 mL sodium hydroxide (NaOH, 0.4 N) 
was added to the mixture and the resultant solution was analyzed by colorimetry at 505 nm. 
SALP levels were estimated using a method previously described by Kind et al. (Kind 
and King, 1954). Briefly, 1 mL of substrate was incubated in 1 mL sodium bicarbonate buffer for 
3 min at 37 °C. To this solution, 100 μL plasma was added, vortexed, and incubated again for 15 
min at 37 °C. After incubation, 0.8 mL sodium hydroxide (0.5 N), 1.2 mL of sodium bicarbonate 
(0.5 N), 1 mL aminoantipyrine (0.6% w/v), and 1 mL potassium ferricyanide were added and 
mixed well. The absorbance of the resulting mixture was measured at 520 nm. 
The total bilirubin in plasma was quantified using the method reported by Malloy et al. 
(Malloy and Evelyn, 1937). Briefly, 5 mL of sulfanilic acid solution (4 mmol/L) was added to 
0.1 mL of sodium nitrite solution (144 mmol/L). To this solution, 0.25 mL plasma was added. 
The mixture was incubated for 10 min at 37 °C and the absorbance measured at 670 nm. 
2.6.2.4 In vivo antioxidant marker enzyme estimation 
The antioxidant potential of pure apigenin and APLC was assessed by the quantitative estimation 
of glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and lipid peroxidase (LPO). 
GSH in rat liver homogenate was estimated using a previously reported method by Ellman 
(Ellman, 1959). First, a precipitating mixture was prepared by dissolving 1.67 g metaphosphoric 
acid, 0.2 g EDTA, and 30 g NaCl in distilled water to make up 100 mL aqueous solution. 
Following the Ellman protocol, 0.2 mL rat liver homogenate, 1.8 mL distilled water, and 0.3 mL 
precipitating mixture were combined and centrifuged at 5000 rpm for 5 min to separate proteins. 
To 1 mL of the supernatant, 1.5 mL phosphate buffer (0.1 M) and 0.5 mL DTNB reagent were 
added. The contents was mixed in a vial and the absorbance of the solution was measured at 412 
nm using UV-visible spectrophotometer (Model: V-630, JASCO International Co. Ltd., Tokyo, 
Japan). The concentration of GSH was expressed as μg/mg of protein. 
A method described by Marklund et al. was used to quantitatively estimate SOD in rat 
liver homogenate (Marklund and Marklund, 1974). Briefly, a reaction mixture was prepared by 
the addition of 2 mL Tris-HCl buffer (75 mM, pH 8.2), 0.6 mL EDTA (6 mM), 20 µL rat liver 
homogenate, and 0.5 mL freshly prepared pyrogallol solution (30 mM). An increase in 
absorbance and change in absorbance/min for the resulting solution was measured against blank 
for 3 min at 30 second intervals  at 420 nm using UV–visible spectrophotometer (Model: V-630, 
JASCO International Co. Ltd., Tokyo, Japan). One unit of enzyme activity is considered 
equivalent to 50% inhibition in the rate of auto-oxidation of pyrogallol. The activity of SOD was 
expressed as units/mg of protein. 
Lipid peroxidase (LPO) in rat liver homogenate was estimated using the method of 
Stocks et al. (Stocks and Dormandy, 1971). To a vial, 0.5 mL rat liver homogenate, 0.2 mL 
sodium lauryl sulfate (8.1% w/v), 1 mL trichloroacetic acid (20% w/v), and 1.5 mL 
thiobarbituric acid (0.8%, w/v) were mixed. This mixture was heated at 100 ºC for 1 h. The 
mixture was then allowed to cool to room temperature (25 ºC) and 1 mL of distilled water was 
added. Centrifugation of the mixture at 4000 rpm for 10 min helped separate the organic layer. 
The absorbance of organic layer was measured at 532 nm using UV–visible spectrophotometer 
(Model: V-630, JASCO International Co. Ltd., Tokyo, Japan). The lipid peroxidation was 
calculated on the basis of the molar extinction coefficient of malondialdehyde (MDA) (1.56 x 
105 M
-1
 cm
-1
), and presented in terms of MDA (nM/g) in hemoglobin.
CAT was quantitatively estimated using the method reported by Beers et al. (Beers and 
Sizer, 1952). Briefly, in a cuvette, 0.1 mL rat liver homogenate and 1.9 mL phosphate buffer (50 
mM, pH 7.4) were added. The reaction was initiated by the addition of 1.0 mL of freshly 
prepared hydrogen peroxide (H2O2, 30 mM). The decomposition rate of H2O2 was measured at 
240 nm using a UV–visible spectrophotometer (Model: V-630, JASCO International Co. Ltd., 
Tokyo, Japan). 
2.6.2.5 Histopathological studies 
At the end of the treatment period, animals from all four treatment groups were euthanized and 
their livers dissected. The isolated livers were maintained in a buffered formalin (10% v/v) 
solution. The livers were then carefully sectioned and stained with hematoxylin and eosin 
reagent. The liver sections were examined under an optical microscope (Model: DM2500, Leica 
Microsystems Inc., Buffalo Grove, IL). The images were captured at a magnification of 400× 
with the attached digital camera. 
2.6.3 Oral bioavailability studies 
2.6.3.1 LC-MS/MS analysis method 
A LC-MS/MS analytical method previously reported in the literature was followed for the 
quantitative evaluation of samples (Duan et al., 2011). The instrument employed for the study 
was a triple quadrupole mass spectrometer (Model: Thermo Scientific™ TSQ Quantum™ 
Access MAX, Thermo Fisher Scientific Inc., Waltham, MA, USA), equipped with an online 
degasser, column heater, and an auto sampler. The stationary phase consisted of a C18 HPLC 
column (100 mm x 4.6 mm, Thermo Scientific™ Hypersil GOLD™, Thermo Fisher Scientific 
Inc., Waltham, MA, USA) with a particle size of 5 µm and maintained at 25 °C. The mobile 
phase consisted of methanol with formic acid (0.1% v/v) and the flow rate was fixed at 1.5 
mL/min. To achieve the best possible resolution of apigenin peaks, the method was standardized 
using quercetin as the internal standard. Chromatographic peaks were detected at 360 nm for 
quantitative analysis. The mass spectrometric analysis of the samples was carried out in a 
positive ionization mode using the selected reaction monitoring (SRM). The ion source 
temperature was 500 °C. The target ions were monitored at m/z of 271.22 for apigenin and 
303.01 for quercetin. The data acquisition, peak integration, and other analysis was performed 
using the associated software (Thermo Scientific™ LCQUAN™, version 2.6, Thermo Fisher 
Scientific Inc., Waltham, MA, USA). 
2.6.3.2 Extraction of apigenin from plasma and sample preparation 
A sample preparation technique previously reported by Chen et al. (Chen et al., 2007) was used 
for the study. Briefly, the laboratory animals were fasted for 12 h with free access to water. The 
animals divided into two groups of six animals each. Group I received a single dose of apigenin 
(100 mg/kg, p.o.) and group II received a single dose of APLC (100 mg/kg, p.o.). At 
predetermined time intervals, the animals were anesthetized and blood samples obtained from 
the retro-orbital plexus were collected into Eppendorf
®
 Safe-Lock microcentrifuge tubes (1.5
mL). The blood samples were then centrifuged at 3000 g for 10 min, the plasma separated, 
collected, and stored at -20 °C prior to analysis. 
For the extraction of apigenin from rat plasma, plasma samples (100 μL) were transferred 
to a test tube and hydrochloric acid (2.0 M) was added to it. The mixture was hydrolyzed at 80 
°C for 1.5 h. After allowing to cool to room temperature1.0 mL ethyl acetate containing 
quercetin (0.05 μg/mL) was added to this reaction mixture. The mixture was vortexed for 3 min 
and then centrifuged at 3500 g for 10 min. After centrifugation, 0.8 mL of the supernatant 
organic phase was transferred to a separate test tube and dried in a vacuum desiccator at room 
temperature. The dried sample was then reconstituted in the mobile phase (100 μL) and analyzed 
by the LC-MS/MS method described above. 
2.6.3.3 Pharmacokinetic studies 
The pharmacokinetic parameters, i.e. maximum plasma concentration (Cmax) and time to reach 
maximum concentration (Tmax), were obtained directly from the concentration–time curve. Other 
parameters such as half-life (t1/2), area under the plasma concentration-time curve from zero to 
the time of the final measured sample (AUC0-t), area under the plasma concentration-time curve 
from zero to infinity (AUC0-∞), clearance (cl/F) and volume of distribution (Vz/F), and the 
relative bioavailability (F) were calculated using a statistical software (WinNonlin
®
, Version 4.1,
Certara USA Inc., Princeton, NJ, USA). 
2.7 Statistical analysis 
The aqueous solubility and in vitro results are presented as mean ± standard deviation. The 
results from the liver function test, in vivo antioxidant activity, and the pharmacokinetic analysis 
are presented as mean ± standard error of mean. The statistical analysis was carried out using 
one-way analysis of variance (ANOVA) followed by Dunnett’s and Student’s t-test. p values < 
0.05 were assumed as statistically significant. 
3 Results and discussion 
3.1 Formulation of apigenin-phospholipids molecular aggregates (Phytosome) 
Flavonoids are generally lipophilic molecules and easily soluble in organic solvents (Jabbari and 
Gharib, 2012). This physical property is exploited in the current study using the solvent 
evaporation method to create a stable phytosome of the flavonoid molecule with phospholipids. 
Existing literature on flavonoids describe the creation of flavonoid-phospholipid aggregates 
using dichloromethane (DCM) in the solvent evaporation method (Bhattacharyya et al., 2014). 
However, we found that apigenin possesses poor solubility in DCM resulting in the precipitation 
of the APLC from DCM. Therefore, the solubility of apigenin and the extent of apigenin 
incorporation was assessed using other solvents. 1, 4-dioxane is an aprotic solvent with low 
dielectric constant, and may assist in solubilization of apigenin and phospholipids to result in the 
formation of stable APLC. We found the binary solvent combination of 1, 4-dioxane: methanol 
(14:6) to be an optimal solvent system for preparing the APLC. Note: The solvent, 1, 4-dioxane 
is used in this study solely for technical reasons, i.e. solubilizing of the formulation 
components. Due to the reported toxicity profile of 1, 4-dioxane in humans, it is strongly 
recommended that alternative solvent be explored for further development and/or 
commercial manufacture of pharmaceutical formulations (Agency for Toxic Substances & 
Disease Registry, 2012). 
3.2 Full-factorial design (32) 
The results of the extent of apigenin incorporation (% yield) from the experimental trials carried 
out using a 3
2
 full factorial design are shown in Table 2. The results indicated that the extent of 
apigenin incorporation was significantly influenced by both the variables studied, i.e. apigenin: 
phospholipid ratio (X1, w:w) and the reaction temperature (X2, °C). For the nine experimental 
batches examined (with different combination of variables), the observed extent of apigenin 
incorporation ranged between 67 and 94%. These data were used to construct a quadratic model 
relating the extent of apigenin incorporation (yield, %) to the tested variables. The resulting 
polynomial equation (Eq. 1, below) was used to draw conclusions based on the magnitude of the 
coefficient, as well as the sign (+, or –) associated with it. 
                                                                  
The estimated coefficient value of b0, b1, b2, and b3 were found to be statistically significant (p < 
0.05), whereas b4 and b5 were found to be not significant (p < 0.05). These observations, coupled 
with the observed value of the correlation coefficient (R
2
 = 0.9989), lead us to conclude that this 
was the best representative model for the study. The positive sign associated with coefficients (b1 
and b2) indicated a positive correlation between the studied variables and the yield (%). The 
influence of the studied variables on the yield (%) is also shown in the form of response surface 
and contour plot (Figure 1). Based on these observations, along with calculations from the 
developed quadratic model, the optimal values for the studied variables, i.e. drug: phospholipid 
ratio (X1, w:w) and the reaction temperature (X2, °C) were found to be 1:2, and 60°C, 
respectively. 
3.3 Validation of the optimized model 
An additional batch of APLC was prepared in order to validate the model using the optimized 
values of the variables,. A comparison between the predicted (theoretical) yield (%) of the APLC 
obtained from the developed model and the actual yield (%) achieved from the prepared 
formulation was carried out. The model-predicted value for the average yield (%) of apigenin in 
the optimized APLC was 93.7%, while the actual yield (%) from the prepared batch was found to 
be 94.87 ± 0.93 %., indicating both applicability, and validity of the developed model. The bias 
(%), calculated using the equation (2) below, was also found to be lower than 3% (-1.25%), 
indicating the relative robustness of the model (Qin et al., 2010). 
         
                              
               
                      
3.4 Physicochemical characterization 
3.4.1 Particle size analysis and zeta potential 
Particle size and zeta potential are valuable predictors of effective distribution and physical 
stability of nanoparticles in a liquid medium. According to Tan et al (Tan et al., 2012), the 
particle size (246.1 nm) of evodiamine–phospholipids complex played a major role in sustained 
release as well as enhancing oral absorption efficiency of evodiamine. Previously published 
reports have suggested that lymphatics play a role in the transport of larger particles (≤ 5 mm) 
whereas, endocytosis is a major pathway for the transport of the smaller particles (≤ 500 nm) 
(LeFevre et al., 1978; Savic et al., 2003). In the present study, the mean particle size of 107.08 ± 
1.30 nm, with polydispersity index of 0.37 ± 0.012 for APLC is appropriate for oral drug 
delivery. The low polydispersity index indicates a narrow range of particle size distribution. 
Zeta potential (ζ) is a measure of stability of a colloidal dispersion. The zeta potential 
value (-22.35 ± 0.30 mV) obtained for APLC was greater than -30 mV, which indicates excellent 
stability of the APLC from flocculation when seen in the context of its low particle size. The zeta 
potential with range (-20 to 30 mV) was earlier demonstrated as a characteristic property of zeta 
potential for attraction followed by flocculation exceeding repulsion forces (Dhore et al., 2016; 
Freitas and Müller, 1998).  The zeta potential value depends on the type and composition of 
phospholipids. In APLC, the low zeta potential value can be elucidated that, the involvement of 
portion phospholipids with generation of negative charge in aqueous environment with 
somewhat neutral pH. Hence, with smaller particle size, lower polydispersity index and modest 
zeta potential value suggested a good physical stability for APLC. 
3.4.2 Differential scanning calorimetry (DSC) 
Differential scanning calorimetry is a well-established techniques for the analysis of thermal 
behavior of a wide variety of materials. Measuring changes in material properties as a function of 
controlled changes in the temperature can provide useful information regarding the melting, 
degradation, compatibility, stability, and other related properties of test materials. In DSC 
thermograms these changes exhibit themselves as enthalpy changes, appearance/disappearance 
of peaks, and changes to a peak’s onset time, shape, and relative area. It also provides 
information of drug-excipient interactions and formation of new entities. 
Figure 2 (A, B, C, and D) shows the DSC thermograms of pure apigenin, pure 
Phospholipon
®
 90H, PM, and APLC, respectively. Pure apigenin (Figure 2A) exhibited a sharp
endothermic (melting) peak at 360.82 ºC, indicating crystalline nature and purity of apigenin. 
The thermograms of Phospholipon
®
 90H (Figure 2B) showed two distinct peaks, first peak of
lower intensity at 67.16º C and a second relatively sharper peak at 84.83º C. While the intensity 
of the first peak can be attributed to the melting, the shape of the second peak indicates a phase-
transition point. This is suggestive of a change from a gel state to a liquid crystalline state, and 
accompanied by isomeric changes to the hydrocarbon segment of the phospholipid, thought to be 
caused due to movements of the polar segment of phospholipid molecule at increasing 
temperatures (Li et al., 2013; Yanyu et al., 2006). The thermogram of the physical mixture (PM) 
(Figure 2C) also shows two dissimilar peaks, i.e. a smaller endothermic peak at 68.34 ºC, and a 
broader peak at 84.84º C. It may be inferred that controlled increase in temperature may cause 
individual components to melt, and form a partial aggregates in situ, whose melting point is 
lower than apigenin or phospholipid (Ruan et al., 2010). Finally, the thermograms of APLC 
(Figure 2D) revealed a completely new peak at 75.05º C, and an the original peaks of apigenin 
and phospholipids appeared to be absent (Galasso et al., 2006). These results are consistent with 
the previously published reports. Thus, on the basis of comparison of above four DSC 
thermograms and previous reports it can be concluded that a stable APLC was formed by weak 
intermolecular interactions (hydrogen bonding, van der Waals interactions, etc.) between 
apigenin and Phospholipon
®
 90H (Lasonder and Weringa, 1990; Venema and Weringa, 1988;
Yanyu et al., 2006). These interactions possibly allow the fatty acid chains of the phospholipid 
molecule rotate freely and surround the apigenin molecule, thus dispersing the apigenin molecule 
into the phospholipid molecule at a molecular level. 
3.4.3 Fourier transform infrared spectroscopy (FTIR) 
The FTIR spectra of pure apigenin, pure Phospholipon
®
 90H, PM, and APLC are shown in
Figure 3A, 3B, 3C, and 3D, respectively (all units are cm
-1
). The spectra of pure apigenin (Figure
3A) revealed characteristic peaks at 3272.34 (O-H), 2894.31 (C-H), 2827.31 (C-H), 1606.77 
(C=O), 1622.10 (C=C), 1557.59 (C=C), and 1500.68 (C=C). These observations were in 
agreement with those reported earlier (Siniša Đorđević et al., 2000). The FTIR spectrum of pure 
Phospholipon
®
 90H (Figure 3B) revealed the characteristic signals at 2918 and 2850, related to
the C–H stretching present in the long fatty acid chain. Additional signals were also observed at 
1738 (C=O stretching in the fatty acid ester), 1236 (P=O stretching), 1091 (P–O–C stretching), 
and 970 [-N
+
(CH2)3] (Semalty et al., 2012). The spectra of the physical mixture (PM) (Figure
3C) showed peaks that were characteristic of the individual components, i.e. apigenin and 
Phospholipon
®
 90H at 3304.20, 2917.46, 2849.95, and 1268.25. The spectra of APLC showed
broad peaks at 3337.96 (O-H stretching in apigenin), 1237.39 (P=O stretching), and 1092.72 (P-
O-C bending). Comparison of the FTIR spectra shows the changes to specific regions of the 
apigenin molecules due to interaction with phospholipids. Changes to the stretching frequency of 
the phenolic O-H of apigenin from 3272.34 to 3337.96 in the phytosome suggests that weak 
intermolecular interactions have been created during the formation of APLC. Moreover, the 
absorption peaks of phospholipids at 1237.39 and 1092.72 were altered completely. It can thus 
be inferred that weak intermolecular interactions between apigenin and phospholipid molecules 
are attributable to the formation of APLC. 
3.4.4 Proton nuclear magnetic resonance (1H-NMR)
Figure 4 (A and B) shows 
1
H–NMR spectra of pure apigenin and the prepared APLC,
respectively. 
1
H chemical shifts are reported in parts per million relative to the TMS peak at
δ0.00. The spectrum of apigenin exhibited characteristic H-shifts described below: 1H NMR (400
MHz, DMSO-d6): δ12.93 (s, 1 H, 5-OH), 10.73 (s, 1 H, 4’-OH), 10.28 (s, 1 H, 7-OH), 7.88 (d, J 
= 8.68 Hz, 2 H, H-2′, H-6′), 6.92 (d, J = 8.68 Hz, 2 H, H-3′, H-5′), 6.71 (s, 1 H, H-3), 6.44 (d, J = 
1.76 Hz, 1 H, H-8), 6.18 (d, J = 1.76 Hz,1 H, H-6). These chemical shifts were compared with 
and were found to be consistent with those of pure apigenin established in literature (Li et al., 
1997; Semalty et al., 2012) The NMR of Phospholipon
®
 90H (Sharma et al., 2015): 
1
H NMR
(400 MHz, DMSO-d6) δ 4.85 (1H, s), 4.08-3.96 (1H, m), 3.83-3.62, (2H, m), 3.38 (1H, s), 3.07 
(15H, s), 2.95 (8H, d, J = 6.8 Hz), 2.27, (1H, s), 1.91 (2H, m), 1.26 (2H, s), 0.95 (23H, s), 0.57 
(3H, s). The 
1
H NMR of APLC is as follows: δ12.92 (s, 1 H, 5-OH), 10.70 (s, 1 H, 4’-OH), 10.39
(s, 1 H, 7-OH), 8.225 (2H), 7.88 (d, J = 8.68 Hz, 2 H, H-2′, H-6′), 7.86,  6.93 (d, J = 8.68 Hz, 2 
H, H-3′, H-5′), 6.71 (s, 1 H, H-3), 6.44 (d, J = 1.76 Hz, 1 H, H-8), 6.18 (d, J = 1.76 Hz,1 H, H-6), 
3.17 (s, 3H), 1.23 (s, 3H). Upon comparison of the chemical shifts of apigenin alongside APLC, 
the key differences emerge in the downfield aromatic region (δ>7) and the upfield aromatic 
region (δ<4). The alkyl side chain of the APLC is seen at δ1.23 and the N-methyl groups 
correspond to the chemical shift at δ 3.17 (Sikarwar et al., 2008). The formation of molecular 
aggregates with apigenin is clearly seen by the change in proton signals in the aromatic region. 
The charged head of the phospholipid molecule is involved in weak intermolecular interactions 
such as hydrogen bond and ion-dipole interactions with the phenolic (4’-OH and 5-OH) regions 
of apigenin. This is supported by the lowered intensity of these proton signals and their distinct 
downfield chemical shifts. This indicates the embedding of apigenin in the phospholipid and thus 
confirms the formation of the APLC. 
3.4.5 Powder x-ray diffractometry (PXRD) 
The x-ray diffractograms of pure apigenin, pure Phospholipon
®
 90H, PM, and APLC are shown
in Figure 5 (A, B, C, and D, respectively). The diffraction patterns of pure apigenin (Figure 5A) 
displayed intense and sharp crystalline peaks at 2θ = 11º, 14º, 16º, 24º, 25º, and 26º, 
characteristic of the crystalline nature of apigenin. Phospholipon
®
 90H (Figure 5B) exhibited a
single, relatively broad peak around 2θ = 20.1º. The absence of any additional well-defined, 
sharp, crystalline peaks in the Phospholipon
®
 90H diffractogram indicated the amorphous nature
of the phospholipid molecule. These observations are consistent with previously published 
reports (Cai et al., 2012). The diffractogram of physical mixture (Figure 5C) exhibited few 
crystalline peaks (related to apigenin) with lower intensity, and a broader peak (associated with 
Phospholipon
®
 90H). The decrease in the intensity of crystalline could be due to the lower
amount of apigenin in the mixture, interference by the phospholipid molecule, or in situ 
formation of a partial aggregates between apigenin and phospholipid, indicating a partial loss of 
the crystalline nature of apigenin (Cai et al., 2012). Finally, the diffractogram of APLC exhibited 
a single broad peak at 2θ = 20.8º, and this diffractogram was similar to that of Phospholipon®
90H, suggesting that apigenin in APLC may be molecularly dispersed in phospholipid matrix, 
and may be present in an amorphous form (Yue et al., 2008). 
3.4.6 Solubility analysis 
The results of the measured solubilities of the pure apigenin, PM, and APLC in water and n-
octanol are shown in the Table 4. Pure apigenin was observed to have poor aqueous solubility 
(~0.6 µg/mL), and a relatively higher solubility in n-octanol (~600 µg/mL), indicating a rather 
lipophilic nature. The physical mixture (PM) revealed a modest, but significant increase in the n-
octanol solubility (~635 µg/mL), and a substantial increase (~10-fold) in the aqueous solubility 
compared to that of pure apigenin (p < 0.01). The prepared phytosome (APLC) however, showed 
a dramatic, and a highly significant (over 35-fold) increase in the aqueous solubility compared to 
that of pure apigenin (p < 0.001). Partial amorphization (reduced molecular crystallinity) of the 
apigenin, and the overall amphiphilic nature of the prepared phytosome can be attributed as the 
main reasons for this observed increase in aqueous solubility (Singh et al., 2012; Xia et al., 
2013). 
3.5 Functional characterization 
3.5.1 In vitro dissolution studies 
Figure 6 compares the dissolution behavior of pure apigenin with that of the prepared APLC in 
phosphate buffer (pH 7.0). The release profiles of apigenin and APLC were found to be similar 
for the first 5 h. After this point, apigenin dissolution appeared to reach a plateau reaching a 
maximum of 27.86 % in 8 h. In contrast, the release of apigenin from the APLC continued to 
increase reaching 50.98% after 12 h. The difference in release rate of apigenin from the two 
formulations can be attributed to the increased solubility and increased wettability of apigenin in 
the prepared phytosome (Perrut et al., 2005). Accordingly, (a) pure apigenin has low aqueous 
solubility which is shown to be improved by the amphiphilic nature of Phospholipon
®
 90H; (b)
apigenin is assumed to change from a crystalline state to a partially amorphous state in the 
APLC, which may extend the rate and extent of dissolution to 12 h; and (c) a change in the 
structural morphology of crystalline apigenin and the amphiphilic nature of Phospholipon
®
 90H
allows for greater wetting of APLC and improved dispersion. Moreover, the sustained release of 
apigenin from APLC may be assumed to occur via a two-step diffusion process. First, in the 
presence of aqueous media, apigenin molecules dissociates from the phytosome. Second, the 
dissociated free apigenin molecules diffuses out of the phospholipid matrix (Dash et al., 2010). 
Thus, APLC was found to significantly enhance both the rate and the extent of apigenin release 
compared to pure apigenin. 
3.5.2 In vivo antioxidant activity 
3.5.2.1 Liver function test 
Carbon tetrachloride (CCl4) is a well-known hepatotoxin used in animal models. Carbon 
tetrachloride is reported to be metabolized by hepatic CYP450 enzymes into reactive oxidative 
species which affect vital organs such as the heart, kidney, brain, blood, and liver (Khan et al., 
2012). Free radicals generated from the xenobiotic transformation of carbon tetrachloride (CCl4) 
bind covalently to cellular macromolecules (e.g. lipids, nucleic acids, proteins) resulting in 
oxidative damage. The results of the influence of apigenin and APLC on the hepatic markers of 
CCl4-induced rat liver damage are described in Table 5. A significant increase in the marker 
enzymes viz., SGOT, SGPT, SALP, and total bilirubin was observed in livers of rats treated with 
CCl4 alone. The administration of apigenin (25 mg/kg, p.o.) for 7 consecutive days prevented 
significantly (p < 0.05) this increase in all marker enzymes except SGPT. The administration of 
APLC (~25 mg/kg apigenin) also prevented the CCl4-induced increase in the levels of all liver 
marker enzymes (including SGPT), and with higher significance (p < 0.01). The results thus 
demonstrate improved hepatoprotective activity of APLC compared to that observed with pure 
apigenin. 
3.5.2.2 In vivo antioxidant marker enzyme estimation 
Levels of liver enzymes such as glutathione (GSH), superoxide dismutase (SOD), catalase 
(CAT), and lipid peroxidase (LPO) have been reported as reliable indicators of antioxidant 
activity (Khan et al., 2012; Maiti et al., 2005; Recknagel et al., 1989). Apigenin has been 
documented as having excellent antioxidant and hepatoprotective properties (Romanova et al., 
2001). In the current study, we examine the effects of pure apigenin and APLC on the levels of 
GSH, SOD, CAT, and LPO on CCl4-treated and naïve mice (Figure 7). CCl4-treated animals 
showed significantly reduced (p < 0.01) levels of GSH compared to the control group of normal 
animals. The group treated with pure apigenin (25 mg/kg, p.o.) significantly (p < 0.05) prevented 
the CCl4-induced reduction in GSH levels. The animal group treated with APLC (~25 mg/kg 
apigenin, p.o.) also showed a prevention of CCl4-induced lowering of GSH levels, albeit with a 
higher significance (p < 0.01) in the liver homogenate. The levels of SOD were found to be 
significantly (p < 0.01) reduced as a result of CCl4 treatment. Treatment with pure apigenin (25 
mg/kg, p.o.) failed to significantly prevent CCl4-induced reduction in SOD levels. In 
comparison, the APLC (~25 mg/kg apigenin, p.o.) treatment was found to result in a significant 
(p < 0.01) prevention of CCl4-induced lowering of SOD levels. CAT levels were found to 
significantly (p < 0.01) decrease as a result of CCl4 treatment.  CCl4-treated animals showed 
significantly reduced (**p < 0.01) CAT level as compared to normal animals. The group treated 
with pure apigenin (25 mg/kg, p.o.) significantly (p < 0.05) prevented this CCl4-induced 
reduction in CAT levels. The animal group treated with APLC (~25 mg/kg apigenin, p.o.) also 
showed a prevention of CCl4-induced lowering of CAT levels, albeit with a higher significance 
(p < 0.01). CCl4 treatment was found to result in significantly (p < 0.01) increased LPO levels 
when compared to normal rats. The group treated with pure apigenin (25 mg/kg, p.o.) 
significantly (p < 0.05) prevented this CCl4-induced increase in LPO levels. The animal group 
treated with APLC (~25 mg/kg apigenin, p.o.) also showed a prevention of CCl4-induced 
increase of LPO levels, albeit with a higher significance (p < 0.01). 
3.5.2.3 Histopathological studies 
A visual assessment of the influence of pure apigenin or APLC treatment on the CCl4-induced 
liver damage was provided by the histopathological investigation of rat liver tissues. Figure 8 (A, 
B, C, and D) shows hematoxylin-eosin stained microscopic (400×) images of liver tissues for the  
treatment groups, i.e. Tween
®
 20, CCl4-treated, pure apigenin + CCl4, or APLC+ CCl4, 
respectively. As shown in Figure 8A, the treatment group that received Tween
®
 20 (1%, v/v) 
exhibited well-preserved cellular organelles indicating healthy, well-functioning liver tissue and 
hepatic cells. The animals treated with CCl4 alone (Figure 8B) showed visible damage and 
degeneration of parenchymal cells, degeneration of the fatty tissues (steatosis), and a significant 
damage to the central lobular region. The administration of pure apigenin (25 mg/kg, p.o.) 
demonstrated a hepatoprotective activity against the CCl4-induced hepatic toxicity (Figure 8C). 
Similarly, the treatment group that received APLC (~25 mg/kg apigenin, p.o.) showed a 
significant protection against CCl4-induced liver damages (Figure 8D). Both pure apigenin and 
APLC treatments appear to restore the normal anatomy of the hepatic cellular structures, which 
can be attributed to the antioxidant properties of apigenin. 
3.5.3 Oral bioavailability studies 
The chromatographic conditions were optimized to improve peak resolution, signal-to-noise 
ratio, and the duration of sample analysis. Apigenin and quercetin (internal standard) are polar 
molecules and different buffers were tested to obtain a mobile phase that produced optimal 
sensitivity and efficiency. Methanol was used as mobile phase and the samples analyzed by LC-
MS/MS with an acceptable run of 5.0 min. We observed that adding formic acid (0.1% v/v) to 
the mobile phase greatly improved the electrospray ionization efficiency of the analytes in the 
positive ion mode. An initial UV scan revealed two peaks for apigenin (268 nm and 335 nm), 
and a single peak for quercetin (368 nm). The choice of an appropriate detection wavelength (λ) 
is critical to ensure a reliable detection of all components of the analyte. Consequently, 350 nm 
was selected as the wavelength of detection for current analysis. 
Apigenin was initially characterized according to its mass spectra from a syringe pump 
infusion analysis, and the daughter ions were revealed in SRM. The heated-electrospray 
ionization (H-ESI) was employed for improved sensitivity and fragmentation. We observed that 
the optimum de-clustering potential for apigenin was +4500V, and thus positive ion mode was 
found to be more sensitive for the analysis of apigenin. We also found that it was ideal to use the 
SRM mode was ideal. In this mode only the daughter ions of apigenin and quercetin were 
fragmented at a collision energy of 39V using nitrogen as a collision medium. In the full-scan 
mass spectra, the daughter ions were observed to be stable and exhibited a high abundance. The 
daughter ions were thus selected as precursor ions for MS/MS fragmentation analysis of apigenin 
and quercetin. The optimized mass transition ion–pairs (m/z) for quantification of apigenin and 
quercetin were established at 271.2/119.0 and 303.0/152.9, respectively. 
The liquid–liquid extraction, protein precipitation, and solid–liquid extraction are among 
the commonly used techniques for extraction of drugs from a plasma matrix. Solid-liquid 
extraction demonstrates excellent recovery and reproducibility. However this technique is 
complicated and expensive. This limits its applications for a rapid  processing of multiple 
samples for bioequivalence and pharmacokinetics studies (Yang et al., 2013). The protein 
precipitation technique exhibits low sample recovery and higher costs due to the use of multiple 
extracting solvents (Barve et al., 2009; DuPont et al., 2004). In the current study, liquid-liquid 
extraction using hydrochloric acid (0.2M) was used to process the plasma samples. During the 
experimental trials, we found that the apigenin and quercetin were easily detected after 
hydrolysis of the plasma with high recovery and accuracy (Chen et al., 2010; Chen et al., 2012; 
Duan et al., 2011). The LC-MS/MS technique was thus effectively applied to monitor the 
concentrations of apigenin in rat plasma for pharmacokinetic evaluation. 
The mean plasma concentration-time profiles of apigenin in the plasma of animals treated 
with pure apigenin (100 mg/kg, p.o.) or APLC (~100 mg/kg apigenin, p.o.) are shown in Figure 
9. The results show a significant increase in the plasma concentration of apigenin in groups
treated with APLC up to 10 h. The plasma concentration-time profiles of both treatment groups, 
i.e. pure apigenin and APLC showed a bimodal pattern. These results are in agreement with 
previous reports where, this bimodal profiles are thought to occur due to enterohepatic 
recirculation (Wan et al., 2007; Zhang et al., 2009). The key pharmacokinetic parameters, as 
estimated using a statistical software (WinNonlin
®
, Version 4.1, Certara USA Inc., Princeton,
NJ, USA) are listed in Table 6. The analysis of data revealed that all pharmacokinetic parameters 
indicative of relative bioavailability, i.e. Cmax, Tmax, and AUC0-∞ were significantly higher in 
animals treated with APLC compared to those treated with pure apigenin. The values of 
elimination half-life (t1/2el) and the elimination rate constant (Kel) remained unchanged for both 
treatment groups. The clearance (cl/F) and volume of distribution (Vz/F) of apigenin was found 
to be significantly lower in the group treated with APLC. These observations indicated a longer 
residence and resulting prolonged duration of action of apigenin after APLC administration. The 
computed bioavailability (F) of apigenin after APLC administration was found to be 82.02%. 
The observed enhancement of the relative bioavailability of apigenin after single oral 
administration of APLC can be attributed to two main factors: (1) phospholipid-based formation 
of molecular aggregates which improves the aqueous solubility of apigenin, leading to enhanced 
intestinal absorption, and, (2) the role of amphiphilic phospholipids as a vesicular carrier matrix 
for apigenin, which may protect it from hepatic first-pass metabolism. While we have observed 
an improved in vivo bioavailability of apigenin with the prepared APLC, it is important to note 
that several factors e.g. dietary lipid intake, can significantly influence the rate and extent of 
absorption and the overall bioavailability of drugs via these systems. As pointed out by Fong et. 
al, the evaluation of solubility and permeability, and the use of appropriate biorelevant media for 
such evaluation is critical in understanding the biopharmaceutical behavior of lipid-based 
formulations (Fong et al., 2016). 
4 Conclusions 
The present work reveals the excellent potential of phospholipid-base molecular aggregates for 
improving the solubility, oral bioavailability and in vivo antioxidant activity of apigenin, a BCS 
Class II drug. The APLC was formulated with the help of a solvent evaporation method and 
optimized using a full factorial design (3
2
) strategy. The APLC formation was supported by
DSC, FTIR, 
1
H-NMR, and PXRD analysis. The data clearly pointed towards the presence of
non-covalent bonding interactions, viz, hydrogen bonding, ion-dipole and van der Waals 
interactions, as key factors in the formation of a stable APLC. Solubility studies demonstrated 
increased solubility of APLC in water as compared to PM or pure apigenin. Furthermore, the rate 
and extent of in vitro apigenin release was significantly enhanced when compared to the 
suspension of pure apigenin. In a CCl4-induced hepatotoxicity model in rats, APLC restored the 
antioxidant enzymes to a significant level, relative to free apigenin. APLC also enhanced oral 
bioavailability of apigenin by demonstrating increased Cmax, Tmax, and AUC parameters as 
compared to apigenin. This study validates the value of employing phospholipids in preparing 
phytosomes with phytoconstituents of low solubility to improve their solubility, oral 
bioavailability, and pharmacological properties. 
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Figure legend 
Figure 1. The response surface plot and contour plots of entrapment efficiency (Y, %) as a 
function of the ratio of apigenin and Phospholipon
®
 90H (X1, w:w), and the reaction temperature
(X2, °C). 
Figure 2. DSC thermograms of (A) pure apigenin, (B) Phospholipon
®
 90H, (C) the physical
mixture (1:1) of apigenin and Phospholipon
®
 90H, and (D) APLC.
Figure 3. FTIR spectra of (A) pure apigenin, (B) Phospholipon
®
 90H, (C) the physical mixture
(1:1) of apigenin and Phospholipon
®
 90H, and (D) APLC.
Figure 4. 
1
H-NMR spectra of (A) apigenin, and (B) APLC.
Figure 5. The X-ray diffractograms of (A) pure apigenin, (B) Phospholipon
®
 90H, (C) the
physical mixture (1:1) of apigenin and Phospholipon
®
 90H, and (D) APLC.
Figure 6. The in-vitro dissolution profiles of apigenin release from apigenin suspension, and 
APLC. Values are mean ± Std. Dev. (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001 (significant 
with respect to pure apigenin). 
Figure 7. Influence of pure apigenin and APLC on rat liver antioxidant marker enzymes, i.e. 
glutathione reductase (GSH) (nmoles/mg of protein), superoxide dismutase (SOD) (units/mg 
protein), catalase (CAT) (units/mg protein), and lipid peroxidase (LPO) (nmoles of MDA 
Figure(s)
released /g tissue). Values are Mean ± Std. Error of Mean (n = 6). *p < 0.05, **p < 0.01 
(significant with respect to control: CCl4-only treated groups). 
Figure 8. Histopathology micrographs (×400) of rat livers. (A) Normal: Tween
®
 20 (1%, v/v,
p.o.), (B) Control: CCL4 + olive oil (1:1, 5 mL/kg, i.p.), (C) Pure apigenin (25 mg/kg, p.o.) +
[CCL4 + olive oil (1:1, 5 mL/kg, i.p., day 7)], and (D) APLC (~25 mg/kg apigenin, p.o.) + [CCL4 
+ olive oil (1:1, 5 mL/kg, i.p., day 7)]. 
Figure 9. Mean plasma concentration-time profile after oral administration of pure apigenin (100 
mg/kg, p.o.) or APLC (~100 mg/kg apigenin, p.o.). Values are mean ± Std. Dev. (n = 6). *p < 
0.05; **p < 0.01, and ***p < 0.001 (significant with respect to pure apigenin treated group). 
Tables 
Table 1. Coded levels and “Real” values for each factor studied 
Variables 
Levels 
-1 0 +1 
Independent  Real values 
Apigenin : Phospholipid ratio (X1, w:w) 1:1 1:2 1:3 
Reaction temperature (X2, °C) 40 50 60 
Dependent 
Extent of apigenin incorporation or Yield (Y, % w/w) 
Table 2. Full factorial design experimental trials along with respectively obtained yield values 
(%, w/w). 
Experimental 
trials 
X1 X2 
Extent of apigenin incorporation, 
or Yield* (%, w/w) 
1 0 +1 93.26 ± 0.82 
2 0 0 90.28 ± 1.75 
3 -1 -1 66.84 ± 1.39 
4 +1 +1 89.70 ± 0.72 
5 +1 -1 84.88 ± 1.47 
6 -1 0 69.31 ± 1.63 
7 +1 0 86.05 ± 1.21 
8 0 -1 87.43 ± 1.32 
9 -1 +1 74.66 ± 0.57 
* Values represent mean ± Std. Dev. (n=3)
Table 3. Solubility analysis of pure apigenin, the physical mixture (1:1) of apigenin and 
Phospholipon
®
 90H (PM), and apigenin- Phospholipon
®
 90H phytosome (APLC).
Sample Aqueous solubility (µg/mL)* n-octanol solubility (µg/mL)* 
Apigenin 0.62   ± 0.88 603.02 ± 0.72 
PM 6.13   ± 1.13 634.77 ± 1.25 
APLC 22.80 ± 1.40 680.24 ± 1.21 
*Data expressed as mean ± Std. Dev.; n = 3
Table(s)
Table 4. Influence of pure apigenin and APLC on rat liver function markers, Serum Glutamic-
Pyruvic Transaminase (SGPT), Serum Glutamic-Oxaloacetic Transaminase (SGOT), Serum 
Alkaline Phosphatase (SALP), and total bilirubin. 
Treatment 
SGPT 
(IU/L)
a
 
SGOT 
(IU/L)
a
 
SALP 
(IU/L)
a
 
Total 
bilirubin 
(mg/dL) 
Normal:  
Tween
®
 20 (1%, v/v, 
p.o.)
36.86 ± 1.30** 38.31 ± 1.15** 134.90 ± 2.14** 0.35 ± 0.02** 
Control:  
CCl4 + olive oil  
(1:1, 5 mL/kg, i.p.) 
76.94 ± 2.96 90.29 ± 3.47 182.20 ± 4.31 0.90 ± 0.05 
Apigenin (25 mg/kg, p.o.) 
+ [CCl4 + olive oil (1:1,  
5 mL/kg, i.p., day 7)] 
63.02 ± 2.45 76.12 ± 1.40* 169.18 ± 2.90* 0.59 ± 0.03* 
APLC (~25mg/kg 
apigenin, p.o.)  
+ [CCl4 + olive oil (1:1, 
5 mL/kg, i.p., day 7)] 
50.90 ± 1.63** 58.07 ± 1.51** 150.25 ± 2.40** 0.46 ± 0.01** 
a
 - IU/L – International Units/Liter of plasma 
All values are Mean ± Std. Error of Mean (n = 6) 
*p < 0.05, **p < 0.01 (significant with respect to control group)
Table 5. Estimated pharmacokinetic parameters after oral administration of pure apigenin (100 
mg/kg, p.o.) or APLC (~100 mg/kg apigenin, p.o.). 
Pharmacokinetic parameters 
Treatment 
Apigenin 
(100 mg/kg, 
p.o.)
APLC 
(~100 mg/kg 
apigenin, p.o.) 
Cmax (µg ml
-1
) 0.14 ± 0.15 0.20 ± 0.25 
Tmax (hours) 2.0 ± 0.23 4.0 ± 0.34 
Area under concentration-time curve (AUC0 – t) (µg ml
-1
 h) 0.84 ± 0.42 1.31 ± 0.46 
Area under concentration-time curve (AUC0–∞) (µg ml
-1
 h) 1.27 ± 0.28 1.95 ± 0.65 
Elimination half-life (t1/2el) (h) 4.80 ± 0.33 4.34 ± 0.52 
Elimination rate constant (Kel) (h
-1
) 0.16 ± 0.04 0.14 ± 0.03 
Clearance (cl/F) [(mg)/(µgml
-1
h
-1
) 78.6 ± 0.45 51.18 ± 0.37 
Volume of distribution (Vz/F) [(mg)/(µgml
-1
h
-1
)] 544.15 ± 0.31 320.72 ± 0.25 
All values are Mean ± Std. Error of Mean (n = 6) 
